08 August 2017

The Swedish tinnitus patch Antinitus's first clinical study - Aktin 1 - is now being published, an important milestone in the company's development.

Sensori AB (publ) has, through its wholly-owned subsidiary Antinitus AB, the pleasure to announce that the company's first clinical study, Aktin 1, has undergone a peer review and is now being published in the International Tinnitus Journal (www.tinnitusjournal.com), reference: Ahnblad P. Pilot Investigation of a Topographical Filter Dermal Patch in Patients with Tinnitus. Int Tinnitus J. 2017; 21(1): 6–12.

This gives the product additional validity and scientific recognition. Empowered by this, Antinitus AB’s program for future clinical studies to further verify and develop the product's effects and performance progresses as expected. This study was, as commissioned by Antinitus AB, carried out by Karolinska Trial Alliance (KTA), a clinical research centre aimed at enabling and conducting clinical studies within the Stockholm County Council (Stockholms Läns Landsting, SLL). KTA is part of Karolinska University Hospital and has, in its capacity as a regional node, been entrusted with the task of offering services to facilitate the process for pharmaceuticals and medical innovations that may benefit patients, as well as developing a strong collaboration between academia and the healthcare and industrial sectors within all of SLL.

‘We welcome the opportunity to communicate our data and respond to questions about the performance of Antinitus. It is important to understand that tinnitus is very a complex issue and represents its very own and heterogeneous entity, since the very perception of it is fundamentally present in all of us as “background noise” ‘, says Tommy Rönngren, founder of and Chairman of the Board at Sensori.

Continuous PMCF (Post-Market Clinical Follow-Up) with feedback from the product's users strengthens the company's conviction that Antinitus provides relief from tinnitus, as well as other quality of life improvements, such as better sleep. Although the company always strives for transparency and to publish its findings, this may be an obstacle in the patenting process, which places high demands on handling the information outward.

Previously, it was believed that the essence of the emergence of tinnitus could be found in the ear; nowadays, however, it is generally agreed that the mechanism is present centrally within the auditory system. This means that tinnitus, as a general concept without a root cause analysis, cannot be compared, assessed or measured like, for example, pain. Tinnitus cannot be “cured”. Updated clinical study recommendations in tinnitus research are more about studying patients at an individual or subgroup level’, Tommy Rönngren continues.

You can find out more here: